COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects
DM Smadja, SJ Mentzer, M Fontenay, MA Laffan… - Angiogenesis, 2021 - Springer
Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is presenting as a systemic disease associated with …
syndrome coronavirus 2 (SARS-CoV-2) is presenting as a systemic disease associated with …
Systematic review of antiphospholipid antibodies in COVID-19 patients: culprits or bystanders?
T Foret, V Dufrost, L Salomon Du Mont, P Costa… - Current Rheumatology …, 2021 - Springer
Purpose of Review COVID-19 patients have a procoagulant state with a high prevalence of
thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) …
thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) …
Untangling the intricacies of infection, thrombosis, vaccination, and antiphospholipid antibodies for COVID-19
N Cimolai - SN Comprehensive Clinical Medicine, 2021 - Springer
Advanced SARS-CoV-2 infections not uncommonly associate with the occurrence of silent
or manifest thrombotic events which may be found as focal or systemic disease. Given the …
or manifest thrombotic events which may be found as focal or systemic disease. Given the …
Lupus anticoagulant is an independent risk factor for non-thrombotic in-hospital mortality in COVID-19 patients
M Constans, R Santiago, L Jimenez, C Motllo… - Thrombosis …, 2021 - Elsevier
Background Thromboembolic disease is a frequent cause of death during SARS CoV-2
infection. Lupus anticoagulant (LA) appears frequently during the acute phase of infection. It …
infection. Lupus anticoagulant (LA) appears frequently during the acute phase of infection. It …